Filing Flows › ADC Therapeutics SA (ADCT) › Q2 2026
ADC Therapeutics SA (ADCT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
ADC Therapeutics SA (ADCT) reported revenue of $19.2M for the second quarter 2026 (Q2 2026), +2% from a year earlier and -8% from the quarter before. Operating margin was -132.0%, net loss $16.6M (86.1% of revenue).
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.2M | -8% | +2% |
| Operating profit | −$25.4M | — | — |
| Net earnings | −$16.6M | — | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $19.2M in Q2 2026, up 2% year over year and down 8% from the previous quarter. Product revenues, net was the largest line at 97% of revenue. Product revenues, net added $549K year over year (up 3%), 134% of the total change. Royalties declined 19%.
Operating costs exceeded revenue by $25.4M, an operating margin of -132.0%. Total costs fell 29% while revenue rose 2%. The fastest-growing cost line was Sales & marketing (+24%). The quarter ended with a net loss of $16.6M, narrower than the previous quarter's $33.0M loss. Non-operating items added $8.8M, -53% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.8M. Non-cash charges added back $4.5M of share-based compensation.
Questions
What was ADC Therapeutics SA's revenue in the second quarter 2026?
ADC Therapeutics SA (ADCT) reported revenue of $19.2M for the second quarter 2026 (Q2 2026), +2% from a year earlier and -8% from the quarter before.
Was ADC Therapeutics SA profitable in the second quarter 2026?
Operating loss was $25.4M (-132.0% of revenue) and net loss $16.6M.